Dazepinil

Dazepinil
Clinical data
Other names	HRP 543
Identifiers
	IUPAC name 2,3-dimethyl-4-phenyl-4,5-dihydro-1,3-benzodiazepine;
CAS Number	75991-50-3 75241-19-9;
PubChem CID	53432;
ChemSpider	48264;
UNII	730EPY2HSM;
ChEMBL	ChEMBL117042;
CompTox Dashboard (EPA)	DTXSID20996719 ;
Chemical and physical data
Formula	C17H18N2
Molar mass	250.345 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=NC2=CC=CC=C2CC(N1C)C3=CC=CC=C3;
	InChI InChI=1S/C17H18N2/c1-13-18-16-11-7-6-10-15(16)12-17(19(13)2)14-8-4-3-5-9-14/h3-11,17H,12H2,1-2H3; Key:STDYWHYUOSSCBO-UHFFFAOYSA-N;

Dazepinil, classified as a tricyclic antidepressant, is a pharmacological compound that has never been approved for medical use. Its mechanism of action involves inhibiting the reuptake of norepinephrine and serotonin at the synaptic cleft, thereby enhancing neurotransmitter availability in the brain.

Dazepinil is a 1,3-benzodiazepine derivative that has been reported to have marked anti-tetrabenazine activity, to inhibit neurotransmitter uptake into rat brain synaptosomes and to lack anticholinergic activity as evidenced by negligible displacement of [3H]quinuclidinyl benzylate from rat brain muscarinic receptors, and by negligible antagonism of the cholinergic stimulation produced by physostigmine or oxotremorine. This suggests that HRP 534 might be clinically useful as a novel antidepressant which is devoid of anticholinergic side-effects.